JNJ buys Ambryx for $2b
BSX buys Axionic for $3.7b
Merck buys Harpoon Therapeutics for 680mm
AbbVie buys Cereval, a neurology and psychiatry company for 8.7b. It has a drug in development for Schizophrenia. Immunogen for $10 billion
PFE buys 43 billion for Seagen
BMS buys Karuna Therapeutics for $14 billion for its neuropsychiatry pipeline.
It is so seductive to think I can find one that will be taken out for many multiples. The advances in health science makes it even more exciting. Simply does not work to buy in hopes of a buyout. Maybe the list is a form of survivorship bias with cherrypicking the ones that do get picked out. I like looking at biotechs because I have become somewhat of a healthnut as I have gotten older; however, I do not get how to price life itself. Pricing anything is difficult.
